about
Few and far between: how HIV may be evading antibody avidityCryoelectron tomography of HIV-1 envelope spikes: further evidence for tripod-like legsProximal glycans outside of the epitopes regulate the presentation of HIV-1 envelope gp120 helper epitopesA Blueprint for HIV Vaccine DiscoveryHIV-1 neutralizing antibodies: understanding nature's pathwaysHIV-1 antibodies from infection and vaccination: insights for guiding vaccine designA Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV ImmunogenComputational Refinement and Validation Protocol for Proteins with Large Variable Regions Applied to Model HIV Env Spike in CD4 and 17b Bound State.Structural plasticity and conformational transitions of HIV envelope glycoprotein gp120Viral CTL escape mutants are generated in lymph nodes and subsequently become fixed in plasma and rectal mucosa during acute SIV infection of macaquesIgG Fc Receptors Provide an Alternative Infection Route for Murine Gamma-Herpesvirus-68Molecular mechanisms of antibody-mediated neutralisation of flavivirus infectionHIV-1 envelope, integrins and co-receptor use in mucosal transmission of HIVStructure determination of an anti-HIV-1 Fab 447-52D–peptide complex from an epitaxially twinned data setCrystal Structure of the HIV-2 Neutralizing Fab Fragment 7C8 with High Specificity to the V3 Region of gp125Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep SequencingStructural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16Glycans, galectins, and HIV-1 infectionThe good and evil of complement activation in HIV-1 infectionV3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodiesNeutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from IndiaBiochemical reconstitution of hemorrhagic-fever arenavirus envelope glycoprotein-mediated membrane fusionImpact of HIV-1 backbone on neutralization sensitivity: neutralization profiles of heterologous envelope glycoproteins expressed in native subtype C and CRF01_AE backboneComputational Design of Hypothetical New Peptides Based on a Cyclotide Scaffold as HIV gp120 InhibitorHuman antibodies that neutralize HIV-1: identification, structures, and B cell ontogeniesMonoclonal antibodies to the V2 domain of MN-rgp120: fine mapping of epitopes and inhibition of α4β7 bindingComparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studiesAnti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypesRational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.HIV/AIDS epidemiology, pathogenesis, prevention, and treatmentReducing the false positive rate in the non-parametric analysis of molecular coevolution.Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).Human immunodeficiency virus vaccine trialsSolution structure, conformational dynamics, and CD4-induced activation in full-length, glycosylated, monomeric HIV gp120Neutralization sensitivity of HIV-1 subtype B' clinical isolates from former plasma donors in China.Visualization of retroviral envelope spikes in complex with the V3 loop antibody 447-52D on intact viruses by cryo-electron tomography.Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics.Comparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopesAn affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10
P2860
Q21090507-688F59C8-9311-4E21-BDF8-F48A15613D68Q21090520-9A1AFCF1-F5DF-43D8-8744-3755CE28A3ACQ24645308-CEB3989B-53F1-4ACC-BBCD-F3B68B912D63Q26829865-30074531-CB04-4633-9B5D-85ADE13BD85FQ27000480-05AD1950-EBE6-40FB-BE81-234B366DCC17Q27022055-BE233DA5-256A-4693-93CD-465A833634B0Q27302081-A83FEF26-F88B-45C7-B690-8BC84AE3451FQ27303608-DB000AF1-ABA2-4AB7-A97D-AFE7CB98C107Q27327645-5D17D3C5-8E29-464C-B5A3-EBE7C026D12AQ27349889-32E0D7F6-4BDB-4958-AA28-EE2C9A1027C3Q27480273-F32CD92A-6E3D-48D0-A0A6-EEFD46120735Q27488337-A0740CFD-C42A-4721-958C-3FD4EB8BEA16Q27497560-12B3D90B-2759-4995-8247-C982F01CAA79Q27650903-F7F4EB82-3FC5-471E-9C14-FC70573CC9FCQ27667679-2D7B27A2-D3E8-4BB9-9015-4DED506DF609Q27671696-551B8703-AD0E-496D-A298-9758BB48663EQ27678312-127C4178-8584-4CB7-B71F-396ABAE63708Q28265115-AD21CAFE-566E-439B-A61F-5C614F8FCA97Q28275986-91DAF11D-EB22-4549-A7CB-F596382E8D80Q28469283-4E8EF123-5C81-470F-AE31-7BAE76649E75Q28483205-8C50B077-9529-4ADD-A8EC-544A615298FAQ28485416-4C489E86-280F-431C-92FC-FB91900BDA24Q28535477-013CD313-BCCB-4A0E-A9FE-E16688E54104Q28550563-07F4EC26-EC1C-4663-87B2-69243CBDB28BQ28602877-34EE2CEC-C2A8-4523-B7DC-B4282AC5819FQ28728517-857090DD-4616-487F-839E-EF58D04600BCQ28749755-3A224FE4-D174-472C-83A1-5731D0498044Q28752503-15425921-5738-4238-8DAE-026224C96652Q29619511-6AD4E782-67DA-4203-8846-10626EEE038EQ30234773-08D50414-39DD-43BD-B0EB-0A06A94DB3FFQ30356074-A90F1E7A-E0F7-4FDB-A076-80F8942C5C6AQ30368774-BCFB693F-5313-4F54-BA06-147A2D3E4F8CQ30379200-109F1F1F-2737-4EE7-899F-B8E9E8E30CA0Q30424366-EA80F3AE-0395-4B48-A697-EC7889F7AD67Q30524225-CD3D7554-E7E5-4E95-A7A7-A8E4438D1E5CQ30537665-F53537B8-AF7F-48E0-AF26-CE6491486602Q30603475-08CD0713-7448-48C3-B7CA-EB97D4BD38C2Q30843874-62B58459-27F3-447D-8167-E48669259B65Q30994182-F8C18072-1CCA-4803-95D8-54DEB3C8B11FQ33272711-89E1C7AC-6D8A-4B6D-BD77-997C24AD493A
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականին հրատարակուած գիտական յօդուած
@hyw
2006 թվականին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
name
GP120: target for neutralizing HIV-1 antibodies
@ast
GP120: target for neutralizing HIV-1 antibodies
@en
GP120: target for neutralizing HIV-1 antibodies
@nl
type
label
GP120: target for neutralizing HIV-1 antibodies
@ast
GP120: target for neutralizing HIV-1 antibodies
@en
GP120: target for neutralizing HIV-1 antibodies
@nl
prefLabel
GP120: target for neutralizing HIV-1 antibodies
@ast
GP120: target for neutralizing HIV-1 antibodies
@en
GP120: target for neutralizing HIV-1 antibodies
@nl
P3181
P1476
GP120: target for neutralizing HIV-1 antibodies
@en
P2093
Dennis R Burton
Ralph Pantophlet
P304
P3181
P356
10.1146/ANNUREV.IMMUNOL.24.021605.090557
P407
P577
2006-01-01T00:00:00Z